Bio-Thera Solutions has closed patient enrollment ahead of schedule for a pivotal Phase 2/3 clinical trial in China of its investigational therapy BAT4406F due to the treatment’s “compelling efficacy” for neuromyelitis optica spectrum disorder (NMOSD). The decision is based on a recommendation from an Independent Data Monitoring Committee…
BAT4406F
BAT4406F, an experimental treatment in the pipeline of Bio-Thera Solutions, reduced the number of circulating immune B-cells that produce disease-causing antibodies in neuromyelitis optica spectrum disorder (NMOSD), translating into less disability for a small group of Chinese patients. That’s according to data from a Phase 1 clinical…
Recent Posts
- NMOSD treatment linked to fewer relapses in real-world study
- I may be a caregiver, but I’m not my wife’s hero; I’m her husband
- Early trial of experimental CAR T-cell therapy seeks people with NMOSD
- Because patients are the reason for the research, we deserve a seat at the table
- Disability in NMOSD patients may worsen even without relapses